Granulocyte colony-stimulating factor for the treatment of hepatic failure: a prospective randomized controlled clinical study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005669

Enrollment

Unknown

Registered

2014-11-02

Start date

2013-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure

Interventions

treatment group:G-CSF+basic therapy

Control:basic therapy

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) age from 17-70 years old; (2) willing to sign the Medical informed Consent; (3) HBV associated liver failure and Alcoholic liver failure.

Exclusion criteria

Exclusion criteria: (1) Prior to G-CSF allergy; (2) With HBV associated liver failure or Alcoholic liver failure co-infected by any other virus, such as HAV, HCV, HDV, HIV et al.; (3) With malignent tumor; (4) Pregnancy, lactation; (5) Active bacterial infection; (6) With severe systemic disease; (7) Participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
survival rate;	—

Secondary

Measure	Time frame
liver function;	—

Countries

China

Contacts

Public ContactHu Jinhua

hjh@medmail.com.cn+86 10 66933405

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026